Official NIH NLM MEDLINE / PubMed Citation • PMID: 42520241
Elinzanetant in postmenopausal women with sleep disturbance: results from the randomized, phase II NIRVANA study.
Sleep
Verbatim Formal Study Abstract
Elinzanetant was estimated to reduce PSG WASO at Week 4 versus placebo (least square [LS]-mean difference = -22.50 minutes, 90% CI: -35.47, -9.52).